MNKD MannKind Corporation - Common Stock
NASDAQ · Biotechnology · 在 SEC EDGAR 上查看 ↗ 收盘 十月 2, 2026 10-K/10-Q 八月 5, 2026
$3.80
· % 处于52周区间
· 高于低点
· 至高点
$2.2352周低点
$6.5152周高点
市值 (MRQ)
$1.18B
P/E (TTM)
-29.2
EPS (TTM)
$-0.13
收入 (TTM)
$394M
MNKD 股票快照 价格、市值、P/E、EPS、ROE、负债/权益、52周范围
价格
$3.80
市值 (MRQ)
$1.18B
P/E (TTM)
-29.2
EPS (TTM)
$-0.13
收入 (TTM)
$394M
ROE (TTM)
71.4%
52周区间
$2–$7
MNKD 股价图表 包含技术指标的日 OHLCV — 平移、缩放和自定义您的视图
区间
条形图
柱状图粒度会根据所选周期进行调整 — 将鼠标悬停在图表上可查看柱状图的开盘价/最高价/最低价/收盘价。
股票拆分
| 除息日 | 拆股 | 类型 |
|---|---|---|
| 2017年3月3日 | 1-for-5 | 反向 |
关于 MannKind Corporation - Common Stock 公司概况（来自维基百科）
MannKind Corporation is a biopharmaceutical company focusing on the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and pulmonary arterial hypertension. Based in Danbury, Connecticut, the company was founded in February 1991.
MannKind Corporation was named after its founder, Alfred E. Mann.
History
Founded in February 1991, the company's present form is a result of a 2003 merger of three companies owned by Alfred E. Mann: Pharmaceutical Discovery Corporation (PDC), the cancer vaccine developer CTL ImmunoTherapies, Inc., and its sister company Allecure Corp, which was developing an allergy vaccine technology. Pharmaceutical Discovery was purchased in 2001 from Solomon Steiner; with that purchase MannKind acquired the Technosphere molecule and Medtone inhaler, upon which was developed its lead product, Afrezza (inhalable insulin).
The FDA approved Afrezza on June 27, 2014.
On August 11, 2014 MannKind entered into an exclusive global licensing agreement with Sanofi for Afrezza sales. Under the agreement, MannKind received $150 million cash from Sanofi, in exchange for sharing profits and losses of sales of Afrezza, with 65% for Sanofi and 35% for MannKind. On January 5, 2016, MannKind Corporation announced the termination of the license and collaboration agreement with Sanofi. By December 2017, the company had lost 11% of its trading volume due to the poor sales.
In March 2020, the company announced it was working with fellow pharmaceutical company Immix Biopharma to try to develop an inhalable treatment for acute respiratory distress syndrome, a lung disease.
Products and product candidates
The firm has developed Afrezza a rapid-acting insulin peaking 12 to 15 minutes after inhalation and exiting the body within 2–3 hours. The inhalation technology uses a miniature, breath-powered inhaler in combination with single-use cartridges containing pre-metered doses. Initial pharmacokinetic studies were followed by studies of safety and efficiency involving Technosphere formulations of different therapeutic proteins.
Leadership
Mann was chief executive officer until January 12, 2015 when Hakan Edstrom became CEO and Mann transitioned to executive chairman.
In November 2015, Hakan Edstrom stepped down as CEO and president. Company founder Alfred Mann stepped in as interim CEO on November 19, 2015. In 2016, Matthew Pfeffer was appointed CEO of MannKind, and served as both CEO and CFO. In May 2017, Michael Castagna was named CEO of the company.
Facilities
MannKind has a large corporate office in Westlake Village, California. The Afrezza manufacturing facility is in Danbury, Connecticut. In 2022, the company moved its official headquarters to Danbury.
来源：维基百科 (英语), CC BY-SA 4.0 · 在维基百科上查看 ↗
行业板块Healthcare
行业Biotechnology
员工591
国家US
10年表现 收入、净利润、利润率和每股收益趋势
收入$349M2016-12-31 → 2025-12-31
EPS$0.022016-12-31 → 2025-12-31
自由现金流$14M2018-12-31 → 2025-12-31
净利率-11.1%2017-12-31 → 2025-12-31
估值与比率
估值 P/E、P/S、P/B、EV/EBITDA 比率 — 该股票是昂贵还是便宜？
| 指标 | 5年趋势 | MNKD | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| P/E (TTM) | -29.25年均值 ≈45.5 | ≈45.5 | · | · | |
| P/S (TTM) | 3.05年均值 ≈9.1 | ≈9.1 | 21.2 | 低估 | |
| 市净率 (MRQ) | -17.55年均值 ≈-14.7 | ≈-14.7 | · | · | |
| 股价/自由现金流 (TTM) | -64.95年均值 ≈7.7 | ≈7.7 | · | · | |
| 市现率 (TTM) | -146.25年均值 ≈27.0 | ≈27.0 | · | · | |
| 市净率（有形资产） (MRQ) | -16.3 | · | · | · |
同行中位数按每项指标的标准化基础计算，可能与本股票显示的TTM/MRQ基础不完全匹配。
盈利能力 毛利率、营业利润率和净利率；股本回报率 (ROE)、资产回报率 (ROA)、投入资本回报率 (ROIC)
| 指标 | 5年趋势 | MNKD | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| 营业利润率 (TTM) | 2.3%5年均值 ≈-17.1% | ≈-17.1% | -308.7% | 顶尖 | |
| EBITDA Margin (息税折旧摊销前利润率) | 11.1%5年均值 ≈-17.1% | ≈-17.1% | -308.7% | 顶尖 | |
| 税前利润率 (TTM) | -12.4%5年均值 ≈-37.8% | ≈-37.8% | · | · | |
| 净利润率 (TTM) | -11.1%5年均值 ≈-37.9% | ≈-37.9% | -214.0% | 顶尖 | |
| ROA (TTM) | -7.6%5年均值 ≈-12.4% | ≈-12.4% | -44.4% | 顶尖 | |
| ROE (TTM) | 71.4%5年均值 ≈10.3% | ≈10.3% | -11.7% | 持平 | |
| ROIC | -316.9%5年均值 ≈-71.2% | ≈-71.2% | -128.0% | 弱 |
财务健康 债务、流动性、偿付能力 — 资产负债表强度
| 指标 | 5年趋势 | MNKD | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| 流动比率 (MRQ) | 1.75年均值 ≈3.3 | ≈3.3 | 10.6 | 低流动性 | |
| 速动比率 (MRQ) | 1.15年均值 ≈2.8 | ≈2.8 | 5.1 | 低流动性 |
成长 营收、每股收益 (EPS) 和净利润增长：同比、3年复合年增长率 (CAGR)、5年复合年增长率 (CAGR)
| 指标 | 5年趋势 | MNKD | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| Revenue YoY (营收同比增长) | 22.2%5年均值 ≈42.6% | ≈42.6% | · | · | |
| Revenue CAGR 3Y (营收3年复合年增长率) | 51.8%5年均值 ≈50.9% | ≈50.9% | · | · | |
| Revenue CAGR 5Y (营收5年复合年增长率) | 39.9% | · | · | · | |
| EPS YoY | -80.0% | · | · | · | |
| Net Income YoY (净利润同比增长) | -78.8% | · | · | · |
资本效率 资产周转率、库存周转率、应收账款周转率
| 指标 | 5年趋势 | MNKD | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| Asset Turnover (资产周转率) | 0.65年均值 ≈0.5 | ≈0.5 | 0.3 | 顶尖 | |
| Inventory Turnover (库存周转率) | 0.85年均值 ≈1.2 | ≈1.2 | · | · | |
| Receivables Turnover (应收账款周转率) | 13.95年均值 ≈14.7 | ≈14.7 | · | · | |
| Revenue / Employee (年营业收入 ÷ 员工人数（报告的 headcount，yfinance）。衍生数据 — 非存储的 SEC-XBRL 概念。) | ≈$590.5K | · | · | · |
价值 · ≈ 5年均值 · 行业中值 · 相对于中值的评判
收益历史 每股收益实际值 vs 预估值，惊喜%，达标率，下次财报日期
平均惊喜
-86.3%
下次报告
十一月 03, 2026
| 期间 | 报告 | EPS Actual | EPS 预期 | 惊喜 |
|---|---|---|---|---|
| 2026年6月30日 | 八月 12, 2026 | $-0.06 | $-0.00 | — |
| 2026年3月31日 | 五月 13, 2026 | $-0.05 | $-0.00 | — |
| 2025年12月31日 | $-0.05 | $0.01 | -440.1% | |
| 2025年9月30日 | $0.07 | $0.02 | 205.9% | |
| 2025年6月30日 | $0.00 | $0.05 | -100.0% | |
| 2025年3月31日 | $0.04 | $0.04 | -10.9% |
完整基本面 所有年度指标 — 损益表、资产负债表、现金流量表
损益表
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $349M | $286M | $199M | $100M | $75M | $65M | $63M | $28M | $12M | $175M | $0 | $0 | |
| Cost of Revenue | $27M | $17M | $21M | $16M | $17M | $15M | $20M | $19M | $17M | $17M | $65M | · | |
| SG&A Expense | $144M | $94M | $94M | $91M | $32M | $25M | $75M | $80M | $75M | $47M | $41M | $79M | |
| Operating Expenses | $88M | $77M | $63M | $57M | $39M | $25M | $108M | $104M | $120M | $107M | $345M | $180M | |
| Operating Income | $39M | $73M | $9M | $-64M | $-47M | $-48M | $-45M | $-77M | $-108M | $67M | $-345M | $-180M | |
| Interest Expense | · | · | $15M | $15M | $15M | · | · | · | · | · | $24M | $20M | |
| Interest Income | $8M | $13M | $6M | $3M | $112.0K | $167.0K | $997.0K | $501.0K | $293.0K | $85.0K | $18.0K | $9.0K | |
| Other Non-op | $-1M | $32.0K | $122.0K | $-102.0K | $-239.0K | $23.0K | $-926.0K | $-437.0K | $13.0K | $-597.0K | $1M | $2M | |
| Pretax Income | $1M | $31M | $-10M | $-87M | $-81M | $-57M | $-52M | $-87M | $-117M | $126M | $-368M | $-198M | |
| Income Tax | $-4M | $3M | $2M | $0 | $0 | $-218.0K | $0 | $240.0K | $51.0K | $0 | $0 | $0 | |
| Net Income | $6M | $28M | $-12M | $-87M | $-81M | $-57M | $-52M | $-87M | $-117M | $126M | $-368M | $-198M | |
| EPS (Basic) | $0.02 | $0.10 | $-0.04 | $-0.34 | $-0.32 | $-0.26 | · | $-0.60 | $-1.13 | $1.37 | $-4.54 | $-2.57 | |
| EPS (Diluted) | $0.02 | $0.10 | $-0.04 | $-0.34 | $-0.32 | $-0.26 | · | $-0.60 | $-1.13 | $1.36 | $-4.54 | $-2.57 | |
| Shares (Basic) | 305,639,000 | 274,415,000 | 267,014,000 | 257,092,000 | 249,244,000 | 222,585,000 | · | 144,136,000 | 104,245,000 | 92,053,000 | 81,233,000 | 77,045,000 | |
| Shares (Diluted) | 314,112,000 | 283,844,000 | 267,014,000 | 257,092,000 | 249,244,000 | 222,585,000 | · | 144,136,000 | 104,245,000 | 92,085,000 | 81,233,000 | 77,045,000 | |
| EBITDA | $39M | $73M | $9M | $-64M | $-47M | $-48M | $-45M | $-77M | $-106M | · | $-334M | $-170M |
资产负债表
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $75M | $46M | $238M | $70M | $124M | $67M | $30M | $71M | $44M | $23M | $59M | $121M | |
| Short-term Investments | $96M | $151M | $57M | $101M | $80M | $0 | $20M | · | · | · | · | · | |
| Receivables | $38M | $12M | $15M | $17M | $5M | $4M | $4M | $4M | $3M | $302.0K | $23.0K | $50M | |
| Inventory | $35M | $28M | $29M | $22M | $7M | $5M | $4M | $4M | $3M | $2M | · | $10M | |
| Prepaid Expense | $47M | $31M | $35M | $25M | $3M | $3M | $3M | $3M | $3M | $4M | $4M | $20M | |
| Current Assets | $292M | $268M | $373M | $235M | $219M | $79M | $61M | $82M | $57M | $77M | $77M | $201M | |
| PP&E (Net) | $82M | $85M | $84M | $45M | $37M | $26M | $27M | $26M | $27M | $29M | $49M | $192M | |
| PP&E (Gross) | $196M | $192M | $186M | $144M | $134M | $123M | $122M | $126M | $128M | $129M | $168M | $310M | |
| Accum. Depreciation | $114M | $107M | $102M | $99M | $98M | $97M | $95M | $100M | $101M | $100M | $120M | $118M | |
| Goodwill | $68M | $2M | $2M | $2M | · | · | · | · | · | · | · | · | |
| Intangibles | $5M | $5M | $1M | $1M | · | · | · | · | · | · | · | · | |
| Other Non-current Assets | $20M | $27M | $7M | $10M | $8M | $3M | $6M | $249.0K | $437.0K | $648.0K | $1M | $848.0K | |
| Total Assets | $792M | $394M | $475M | $295M | $321M | $109M | $94M | $108M | $85M | $107M | $126M | $394M | |
| Accounts Payable | $9M | $7M | $10M | $11M | $7M | $6M | $5M | $5M | $7M | $3M | $16M | $7M | |
| Accrued Liabilities | $65M | $40M | $42M | $36M | $27M | $20M | $16M | $15M | $12M | $8M | $8M | $26M | |
| Short-term Debt | · | · | · | · | · | · | $5M | · | · | · | · | · | |
| Current Liabilities | $171M | $82M | $104M | $67M | $48M | $74M | $66M | $75M | $88M | $92M | $268M | $403M | |
| Capital Leases | $11M | $12M | $4M | $5M | $1M | $1M | $3M | · | · | · | · | · | |
| Other Non-current Liabilities | · | · | · | · | $5M | · | · | · | · | · | $15M | $12M | |
| Total Liabilities | $843M | $473M | $721M | $546M | $531M | $289M | $284M | $283M | $299M | $291M | $477M | $468M | |
| Long-term Debt | $355M | $36M | $269M | $273M | $281M | $122M | $119M | $102M | $157M | · | · | · | |
| Total Debt | · | · | · | · | · | · | $5M | · | · | · | · | · | |
| Common Stock | $3M | $3M | $3M | $3M | $3M | $2M | $2M | $2M | $1M | $957.0K | $4M | $4M | |
| Retained Earnings | $-3.20B | $-3.20B | $-3.23B | $-3.22B | $-3.13B | $-3.05B | $-2.99B | $-2.94B | $-2.85B | $-2.74B | $-2.86B | $-2.49B | |
| AOCI | $115.0K | $1M | · | · | · | · | $-19.0K | $-19.0K | $-18.0K | $-24.0K | $-20.0K | $-14.0K | |
| Stockholders' Equity | $-51M | $-79M | $-246M | $-251M | $-209M | $-180M | $-191M | $-175M | $-215M | $-184M | $-350M | $-74M | |
| Liabilities + Equity | $792M | $394M | $475M | $295M | $321M | $109M | $94M | $108M | $85M | $107M | $126M | $394M | |
| Shares Outstanding | 307,832,587 | 302,959,782 | 270,034,495 | 263,793,305 | 251,477,562 | 242,117,089 | 211,787,573 | 187,029,967 | 119,053,414 | 95,680,831 | 85,734,188 | 406,059,089 |
现金流
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $12M | $7M | $5M | $3M | $2M | $2M | $972.0K | $3M | $2M | $2M | $11M | $10M | |
| Stock-based Comp | $24M | $21M | $18M | $13M | $12M | $7M | $6M | $7M | $5M | $5M | $9M | $49M | |
| Deferred Tax | $-19M | $4M | $7M | $-10M | $-20M | $-5M | $-5M | $-11M | $-260M | $48M | $-80M | $-66M | |
| Amort. of Intangibles | $4M | · | · | · | · | · | · | · | · | · | · | · | |
| Restructuring | · | · | · | · | · | · | · | · | · | $2M | $6M | $2M | |
| Other Non-cash | · | · | · | · | · | · | · | · | $306M | · | $291M | $144M | |
| Operating Cash Flow | $18M | $43M | $34M | $-81M | $-62M | $-28M | $-88M | $-38M | $-65M | $-78M | $-57M | $4M | |
| CapEx | $5M | $10M | $42M | $8M | $11M | $801.0K | $3M | $354.0K | · | $1M | $10M | $24M | |
| Investing Cash Flow | $-305M | $-97M | $-2M | $5M | $-152M | $15M | $-23M | $-234.0K | $17M | $-1M | · | · | |
| Debt Issued | · | · | · | · | · | $5M | · | · | · | · | · | $20M | |
| Net Debt Issued | · | · | · | · | · | $5M | · | · | · | · | · | · | |
| Stock Issued | · | · | · | · | · | · | · | · | $564.0K | $893.0K | $28M | · | |
| Net Stock Activity | · | · | · | · | · | · | · | · | $564.0K | · | $28M | · | |
| Financing Cash Flow | $315M | $-137M | $137M | $21M | $270M | $50M | $70M | $61M | $74M | $43M | · | · | |
| Net Change in Cash | $29M | $-191M | $169M | $-54M | $57M | $37M | $-41M | $23M | $25M | $-36M | $-62M | $50M | |
| Taxes Paid | $2M | $4M | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $14M | $33M | $-8M | $-88M | $-73M | $-29M | $-91M | $-38M | · | · | $-68M | $-20M | |
| Levered FCF | · | · | $-26M | $-98M | · | · | · | · | · | · | $-92M | · |
盈利能力
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 11.1% | 25.4% | 4.4% | -64.3% | -62.3% | -73.6% | -70.8% | -274.9% | -921.1% | · | · | · | |
| Net Margin | 1.7% | 9.7% | -6.0% | -87.6% | -107.3% | -87.9% | -82.3% | -312.2% | -999.0% | · | · | · | |
| Pretax Margin | 0.40% | 10.7% | -5.2% | -87.6% | -107.3% | -88.2% | -82.3% | -311.3% | -998.6% | · | · | · | |
| EBITDA Margin | 11.1% | 25.4% | 4.4% | -64.3% | -62.3% | -73.6% | -70.8% | -274.9% | -905.8% | · | · | · | |
| ROA | 0.99% | 6.3% | -3.1% | -28.4% | -37.7% | -56.6% | -51.5% | -90.5% | -122.4% | · | -141.5% | -60.8% | |
| ROE | -11.1% | -19.1% | 4.8% | 35.8% | 41.1% | 31.2% | 27.7% | 45.7% | 58.9% | · | 173.8% | 379.7% | |
| ROIC | -316.9% | -83.2% | -4.1% | 25.6% | 22.5% | 26.5% | 24.0% | 43.9% | 50.4% | · | 98.4% | · |
流动性与偿付能力
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.7 | 3.3 | 3.6 | 3.5 | 4.5 | 1.1 | 0.9 | 1.1 | 0.7 | · | 0.3 | 0.5 | |
| Quick Ratio | 1.2 | 2.6 | 3.0 | 2.8 | 4.3 | 1.0 | 0.8 | 1.0 | 0.5 | · | 0.2 | 0.4 | |
| Debt / Equity | · | · | · | · | · | · | -0.0 | · | · | · | · | · | |
| Interest Coverage | · | · | 0.6 | -6.7 | · | · | · | · | · | · | -14.3 | -8.8 |
效率
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.6 | 0.7 | 0.5 | 0.3 | 0.4 | 0.6 | 0.6 | 0.3 | 0.1 | · | 0.0 | · | |
| Inventory Turnover | 0.8 | 0.6 | 0.8 | 1.1 | 2.8 | 3.3 | 5.2 | 6.2 | 6.9 | · | · | · | |
| Receivables Turnover | 13.9 | 21.4 | 12.6 | 9.3 | 16.4 | 16.9 | 16.7 | 8.2 | 7.6 | · | 0.0 | · |
每股
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-0.17 | $-0.26 | $-0.91 | $-0.95 | $-0.83 | $-0.75 | $-0.90 | $-0.94 | $-1.80 | · | $-0.82 | $-0.18 | |
| Revenue / Share | $1.11 | $1.01 | $0.75 | $0.39 | · | · | · | $0.19 | $0.11 | · | · | · | |
| Cash Flow / Share | $0.06 | $0.15 | $0.13 | $-0.31 | · | · | · | $-0.26 | $-0.62 | · | · | · | |
| Cash / Share | $0.24 | $0.15 | $0.88 | $0.26 | $0.49 | $0.28 | $0.14 | $0.38 | $0.37 | · | $0.14 | $0.30 | |
| EPS (TTM) | $0.02 | $0.10 | $-0.04 | $-0.34 | $-0.32 | $-0.26 | $-0.63 | $-0.60 | $-1.13 | $1.36 | $-4.54 | $-2.57 |
增长率
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 22.2% | 43.5% | 99.4% | 32.2% | 15.8% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 51.8% | 55.8% | 45.1% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 39.9% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | -80.0% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | -78.8% | · | · | · | · | · | · | · | · | · | · | · |
估值 (TTM)
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $349M | $286M | $199M | $100M | $75M | $65M | $63M | $28M | $12M | $175M | $0 | $0 | |
| Net Income TTM | $6M | $28M | $-12M | $-87M | $-81M | $-57M | $-52M | $-87M | $-117M | $126M | $-368M | $-198M | |
| Market Cap | $1.75B | $1.95B | $983M | $1.39B | $1.10B | $758M | $273M | $198M | $276M | · | $3.11B | $10.60B | |
| Enterprise Value | · | · | · | · | · | · | $228M | · | · | · | · | · | |
| P/E | 283.5 | 64.3 | -91.0 | -15.5 | -13.7 | -12.0 | -2.0 | -1.8 | -2.1 | 2.4 | -1.6 | -10.2 | |
| P/S | 5.0 | 6.8 | 4.9 | 13.9 | 14.6 | 11.6 | 4.3 | 7.1 | 23.5 | · | · | · | |
| P/B | -34.2 | -24.7 | -4.0 | -5.5 | -5.2 | -4.2 | -1.4 | -1.1 | -1.3 | · | -8.9 | -143.7 | |
| P / Cash Flow | 95.6 | 45.8 | 28.8 | -17.2 | -17.8 | -26.9 | -3.1 | -5.3 | -4.3 | · | -54.3 | 2593.8 | |
| P / FCF | 127.5 | 59.4 | -117.8 | -15.7 | -15.0 | -26.2 | -3.0 | -5.2 | · | · | -46.0 | -529.6 | |
| EV / EBITDA | · | · | · | · | · | · | -5.1 | · | · | · | · | · | |
| EV / FCF | · | · | · | · | · | · | -2.5 | · | · | · | · | · | |
| EV / Revenue | · | · | · | · | · | · | 3.6 | · | · | · | · | · | |
| Earnings Yield | 0.35% | 1.6% | -1.1% | -6.5% | -7.3% | -8.3% | -48.8% | -56.6% | -48.7% | 42.5% | -62.6% | -9.8% |
损益表
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $109M | $90M | $112M | $82M | $77M | $78M | $77M | $70M | $72M | $66M | $58M | $51M | $49M | $41M | $36M | $33M | |
| Cost of Revenue | $14M | $8M | $14M | $4M | $5M | $4M | $5M | $3M | $6M | $4M | $6M | $4M | $5M | $6M | $4M | $5M | |
| SG&A Expense | $58M | $54M | $58M | $29M | $32M | $25M | $24M | $24M | $24M | $22M | $61M | $11M | $12M | $11M | $64M | $9M | |
| Operating Expenses | $30M | $92M | $-103M | $63M | $21M | $56M | $-86M | $57M | $56M | $50M | $18M | $14M | $14M | $16M | $16M | $17M | |
| Operating Income | $-350.0K | $-2M | $-8M | $19M | $5M | $22M | $26M | $13M | $17M | $17M | $8M | $5M | $2M | $-6M | $-13M | $-10M | |
| Interest Expense | · | · | · | · | · | · | · | · | $6M | $3M | · | $3M | $7M | $3M | · | $3M | |
| Interest Income | $1M | $1M | $2M | $3M | $2M | $2M | $3M | $3M | $3M | $3M | $2M | $2M | $2M | $1M | $957.0K | $663.0K | |
| Other Non-op | $-5M | $-3M | $23M | $-11M | $-4M | $-9M | $24M | $110.0K | $-18M | $-6M | $-164.0K | $318.0K | $-143.0K | $111.0K | $105.0K | $-207.0K | |
| Pretax Income | $-19M | $-16M | $-21M | $8M | $940.0K | $14M | $8M | $13M | $-2M | $11M | $3M | $2M | $-5M | $-10M | $-18M | $-14M | |
| Income Tax | $-106.0K | $253.0K | $-5M | $-204.0K | $272.0K | $459.0K | $1M | $1M | $323.0K | $264.0K | $2M | $0 | $0 | $0 | · | $0 | |
| Net Income | $-19M | $-17M | $-16M | $8M | $668.0K | $13M | $7M | $12M | $-2M | $11M | $1M | $2M | $-5M | $-10M | $-18M | $-14M | |
| EPS (Basic) | $-0.06 | $-0.05 | $-0.05 | $0.03 | $0.00 | $0.04 | $0.03 | $0.04 | $-0.01 | $0.04 | $0.01 | $0.01 | $-0.02 | $-0.04 | $-0.07 | $-0.06 | |
| EPS (Diluted) | $-0.06 | $-0.05 | $-0.05 | $0.03 | $0.00 | $0.04 | $0.03 | $0.04 | $-0.01 | $0.04 | $0.01 | $0.01 | $-0.02 | $-0.04 | $-0.07 | $-0.06 | |
| Shares (Basic) | 309,191,000 | 308,267,000 | · | 306,806,000 | 304,954,000 | 303,481,000 | · | 274,998,000 | 273,056,000 | 270,356,000 | · | 268,732,000 | 265,626,000 | 263,969,000 | · | 259,300,000 | |
| Shares (Diluted) | 309,191,000 | 308,267,000 | · | 311,638,000 | 311,484,000 | 320,897,000 | · | 284,693,000 | 273,056,000 | 324,733,000 | · | 323,770,000 | 265,626,000 | 263,969,000 | · | 259,300,000 | |
| EBITDA | · | $-2M | · | $19M | $5M | $22M | · | $13M | $17M | $17M | · | $5M | $2M | $-6M | · | $-10M |
资产负债表
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $53M | $53M | $75M | $127M | $57M | $47M | $46M | $62M | $97M | $193M | · | $83M | $86M | $86M | · | $54M | |
| Short-term Investments | $58M | $81M | $96M | $133M | $122M | $134M | $151M | $189M | $151M | $107M | · | $58M | $58M | $80M | · | $111M | |
| Receivables | $43M | $28M | $38M | $17M | $27M | $29M | $12M | $18M | $23M | $20M | · | $22M | $28M | $20M | · | $23M | |
| Inventory | $44M | $49M | $35M | $27M | $28M | $29M | $28M | $27M | $25M | $26M | · | $27M | $25M | $22M | · | $18M | |
| Prepaid Expense | $47M | $40M | $47M | $54M | $44M | $34M | $31M | $31M | $30M | $36M | · | $36M | $33M | $15M | · | $12M | |
| Current Assets | $246M | $251M | $292M | $359M | $279M | $274M | $268M | $328M | $326M | $383M | · | $226M | $230M | $223M | · | $218M | |
| PP&E (Net) | $85M | $83M | $82M | $83M | $83M | $84M | $85M | $85M | $85M | $84M | · | $80M | $70M | $55M | · | $41M | |
| PP&E (Gross) | $203M | $198M | $196M | $195M | $194M | $192M | $192M | $192M | $190M | $186M | · | $182M | $170M | $154M | · | $140M | |
| Accum. Depreciation | $118M | $116M | $114M | $113M | $111M | $109M | $107M | $107M | $105M | $103M | · | $101M | $100M | $100M | · | $99M | |
| Goodwill | $68M | $68M | $68M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | · | $2M | $2M | $2M | · | $3M | |
| Intangibles | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $1M | $1M | · | $1M | $1M | $1M | · | $1M | |
| Other Non-current Assets | $17M | $22M | $20M | $19M | $20M | $28M | $27M | $26M | $16M | $7M | · | $8M | $8M | $16M | · | $17M | |
| Total Assets | $732M | $744M | $792M | $495M | $412M | $410M | $394M | $464M | $444M | $481M | · | $320M | $313M | $298M | · | $294M | |
| Accounts Payable | $11M | $16M | $9M | $7M | $10M | $5M | $7M | $6M | $10M | $7M | · | $17M | $17M | $14M | · | $10M | |
| Accrued Liabilities | $61M | $59M | $65M | $31M | $31M | $40M | $40M | $37M | $41M | $42M | · | $32M | $37M | $33M | · | $30M | |
| Current Liabilities | $143M | $135M | $171M | $109M | $112M | $116M | $82M | $72M | $80M | $100M | · | $96M | $97M | $82M | · | $60M | |
| Capital Leases | $10M | $10M | $11M | $10M | $11M | $11M | $12M | $12M | $3M | $4M | · | $4M | $5M | $5M | · | $6M | |
| Total Liabilities | $800M | $804M | $843M | $539M | $467M | $469M | $473M | $674M | $670M | $711M | · | $572M | $574M | $554M | · | $532M | |
| Long-term Debt | $319M | $319M | $355M | $110M | $36M | $36M | $36M | $228M | $228M | $264M | · | $273M | $274M | $274M | · | $273M | |
| Common Stock | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | · | $3M | $3M | $3M | · | $3M | |
| Retained Earnings | $-3.23B | $-3.21B | $-3.20B | $-3.18B | $-3.19B | $-3.19B | $-3.20B | $-3.21B | $-3.22B | $-3.22B | · | $-3.23B | $-3.23B | $-3.23B | · | $-3.20B | |
| AOCI | $-19.0K | $-4.0K | $115.0K | $137.0K | $1M | $1M | $1M | $588.0K | · | · | · | $443.0K | $443.0K | · | · | $-1M | |
| Stockholders' Equity | $-67M | $-59M | $-51M | $-45M | $-55M | $-59M | $-79M | $-210M | $-226M | $-230M | $-246M | $-252M | $-260M | $-255M | $-251M | $-238M | |
| Liabilities + Equity | $732M | $744M | $792M | $495M | $412M | $410M | $394M | $464M | $444M | $481M | · | $320M | $313M | $298M | · | $294M | |
| Shares Outstanding | 309,911,682 | 308,907,331 | 307,832,587 | 307,027,189 | 306,332,133 | 303,918,969 | 302,959,782 | 275,775,038 | 274,467,247 | 270,801,781 | · | 269,543,539 | 268,235,145 | 264,278,760 | · | 263,156,165 |
现金流
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $6M | $6M | $6M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $1M | $1M | $1M | $1M | $1M | $-427.0K | |
| Stock-based Comp | $10M | $6M | $7M | $4M | $8M | $5M | $6M | $5M | $6M | $4M | $4M | $5M | $6M | $4M | $3M | $4M | |
| Amort. of Intangibles | $4M | $4M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-18M | $-5M | $-8M | $24M | $9M | $-6M | $23M | $9M | $4M | $7M | $22M | $9M | $3M | $1M | $-2M | $-28M | |
| CapEx | $5M | $2M | $2M | $1M | $1M | $330.0K | $3M | $1M | $3M | $2M | $6M | $11M | $17M | $8M | $5M | $271.0K | |
| Investing Cash Flow | $18M | $19M | $-292M | $-25M | $6M | $6M | $48M | $-41M | $-55M | $-48M | $-8M | $-12M | $4M | $14M | $15M | $27M | |
| Financing Cash Flow | $559.0K | $-35M | $247M | $72M | $-6M | $1M | $-87M | $-2M | $-45M | $-3M | $142M | $-283.0K | $-6M | $1M | $3M | $20M | |
| Net Change in Cash | $97.0K | $-22M | $-53M | $70M | $10M | $975.0K | $-16M | $-34M | $-96M | $-45M | $155M | $-3M | $315.0K | $16M | $15M | $19M | |
| Taxes Paid | $753.0K | $63.0K | $549.0K | $80.0K | $869.0K | $207.0K | $2M | $236.0K | · | · | · | · | · | · | · | · | |
| Free Cash Flow | · | $-7M | · | · | · | $-7M | · | · | · | $4M | · | · | · | $-7M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $2M | · | · | · | $-10M | · | · |
盈利能力
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | -1.8% | · | 23.0% | 6.9% | 28.4% | · | 18.2% | 22.9% | 25.2% | · | 9.9% | 3.5% | -14.8% | · | -29.3% | |
| Net Margin | · | -18.4% | · | 9.7% | 0.87% | 16.8% | · | 16.5% | -2.8% | 16.0% | · | 3.4% | -10.8% | -24.1% | · | -44.0% | |
| Pretax Margin | · | -18.1% | · | 9.5% | 1.2% | 17.4% | · | 18.4% | -2.3% | 16.4% | · | 3.4% | -10.8% | -24.1% | · | -44.0% | |
| EBITDA Margin | · | -1.8% | · | 23.0% | 6.9% | 28.4% | · | 18.2% | 22.9% | 25.2% | · | 9.9% | 3.5% | -14.8% | · | -29.3% | |
| ROA | · | -2.9% | · | 1.7% | 0.16% | 2.9% | · | 2.9% | -0.53% | 2.7% | · | 0.56% | -1.8% | -3.2% | · | -5.4% | |
| ROE | · | 28.2% | · | -6.3% | -0.48% | -9.1% | · | -5.0% | 0.83% | -4.4% | · | -0.70% | 2.1% | 4.0% | · | 6.8% | |
| ROIC | · | 2.9% | · | -43.5% | -6.8% | -36.8% | · | -5.5% | -8.8% | -7.1% | · | -2.0% | -0.66% | 2.4% | · | · |
流动性与偿付能力
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | · | 1.9 | · | 3.3 | 2.5 | 2.4 | · | 4.5 | 4.1 | 3.8 | · | 2.3 | 2.4 | 2.7 | · | 3.7 | |
| Quick Ratio | · | 1.2 | · | 2.5 | 1.8 | 1.8 | · | 3.7 | 3.4 | 3.2 | · | 1.7 | 1.8 | 2.3 | · | 3.2 | |
| Interest Coverage | · | · | · | · | · | · | · | · | 2.7 | 6.5 | · | 1.8 | 0.3 | -2.5 | · | · |
效率
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.1 | · | 0.1 | |
| Inventory Turnover | · | 0.2 | · | 0.2 | 0.2 | 0.1 | · | 0.1 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.4 | · | 0.4 | |
| Receivables Turnover | · | 3.2 | · | 4.6 | 3.0 | 3.2 | · | 3.5 | 2.8 | 3.3 | · | 2.3 | 2.3 | 2.8 | · | 2.0 |
每股
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | · | $-0.19 | · | $-0.15 | $-0.18 | $-0.19 | · | $-0.76 | $-0.82 | $-0.85 | · | $-0.93 | $-0.97 | $-0.97 | · | $-0.90 | |
| Revenue / Share | · | $0.29 | · | $0.26 | $0.25 | $0.24 | · | $0.25 | $0.27 | $0.20 | · | $0.16 | $0.18 | $0.15 | · | $0.13 | |
| Cash Flow / Share | · | $-0.02 | · | · | · | $-0.02 | · | · | · | $0.02 | · | · | · | $0.00 | · | · | |
| Cash / Share | · | $0.17 | · | $0.41 | $0.19 | $0.16 | · | $0.23 | $0.35 | $0.71 | · | $0.31 | $0.32 | $0.32 | · | $0.21 | |
| EPS (TTM) | $-0.08 | $-0.07 | · | $0.10 | $0.11 | $0.10 | · | $0.08 | $0.05 | $0.04 | · | $-0.12 | $-0.19 | $-0.28 | · | $-0.38 |
估值 (TTM)
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $358M | $361M | · | $314M | $302M | $298M | · | $267M | $248M | $225M | · | $177M | $158M | $128M | · | $76M | |
| Net Income TTM | $-27M | $-24M | · | $29M | $33M | $30M | · | $22M | $12M | $8M | · | $-31M | $-47M | $-71M | · | $-98M | |
| Market Cap | · | $757M | · | $1.65B | $1.15B | $1.53B | · | $1.73B | $1.43B | $1.23B | · | $1.11B | $1.09B | $1.08B | · | $813M | |
| P/E | -53.2 | -35.0 | · | 53.7 | 34.0 | 50.3 | · | 78.6 | 104.4 | 113.2 | · | -34.4 | -21.4 | -14.6 | · | -8.1 | |
| P/S | · | 2.1 | · | 5.3 | 3.8 | 5.1 | · | 6.5 | 5.8 | 5.5 | · | 6.3 | 6.9 | 8.4 | · | 10.7 | |
| P/B | · | -12.8 | · | -37.0 | -20.8 | -26.1 | · | -8.3 | -6.3 | -5.3 | · | -4.4 | -4.2 | -4.2 | · | -3.4 | |
| P / Cash Flow | · | -141.1 | · | · | · | -239.7 | · | · | · | 183.0 | · | · | · | 937.3 | · | · | |
| Earnings Yield | -1.9% | -2.9% | · | 1.9% | 2.9% | 2.0% | · | 1.3% | 0.96% | 0.88% | · | -2.9% | -4.7% | -6.8% | · | -12.3% |
最近期在左侧 · 空值显示为 ·
财务报表 损益表、资产负债表、现金流量表 — 年度，近5年
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 收入 | $349M | $286M | $199M | $100M | $75M |
| 营业利润率 % | 11.1% | 25.4% | 4.4% | -64.3% | -62.3% |
| 净收入 | $6M | $28M | $-12M | $-87M | $-81M |
| 稀释后每股收益 (EPS) | $0.02 | $0.10 | $-0.04 | $-0.34 | $-0.32 |
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 流动比率 | 1.7 | 3.3 | 3.6 | 3.5 | 4.5 |
| 速动比率 | 1.2 | 2.6 | 3.0 | 2.8 | 4.3 |
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 自由现金流 | $14M | $33M | $-8M | $-88M | $-73M |
机构持有人 (13F) 271 家申报者 · $883.4M 总计 · 截至 2026年9月30日
在其季度SEC表格13F中报告持有此股票的机构。仅限多头头寸；单个申报人可能因单独的期权腿而出现两次。 大的抵消性看跌/看涨腿通常反映做市或对冲库存，而非方向性判断。
持有人
271
持有价值
$883.4M
新仓位
51
已退出持仓
39
机构活动 — Q2 2026 与上一季度对比
| 新仓位 | 已退出持仓 | 增加 | 减少 | 净股数变动 |
|---|---|---|---|---|
| 51 (0 与上一季度对比) | 39 (-8 与上一季度对比) | 98 (+12 与上一季度对比) | 63 (-7 与上一季度对比) | +1.9M |
与Q1 2026对比。 SEC 13F表格的提交截止日期是季度末后45天，外加少量延迟提交的缓冲期——在此窗口期内的季度将被跳过，优先显示最近一个已完整报告的季度对。
| 机构 | 价值 | 股份 | % 已追踪的13F | 类型 |
|---|---|---|---|---|
| BlackRock, Inc. | $136887530 | 32133223 | 15.50% | 股份 |
| VANGUARD GROUP INC | $101384549 | 17880873 | 11.48% | 股份 |
| Rubric Capital Management LP | $76680000 | 18000000 | 8.68% | 股份 |
| STATE STREET CORP | $68901423 | 16174043 | 7.80% | 股份 |
| VANGUARD CAPITAL MANAGEMENT LLC | $56101610 | 13169392 | 6.35% | 股份 |
| GEODE CAPITAL MANAGEMENT, LLC | $33861886 | 7947203 | 3.83% | 股份 |
| WELLINGTON MANAGEMENT GROUP LLP | $33418878 | 7844807 | 3.78% | 股份 |
| Frazier Life Sciences Management, L.P. | $28116000 | 6600000 | 3.18% | 股份 |
| Deep Track Capital, LP | $25560000 | 6000000 | 2.89% | 股份 |
| 180 WEALTH ADVISORS, LLC | $21126835 | 4959351 | 2.39% | 股份 |
| FMR LLC | $17470455 | 4101046 | 1.98% | 股份 |
| TSP Capital Management Group, LLC | $16923596 | 3972675 | 1.92% | 股份 |
| AQR CAPITAL MANAGEMENT LLC | $16225589 | 3808824 | 1.84% | 股份 |
| MORGAN STANLEY | $14802946 | 3474870 | 1.68% | 股份 |
| BRAIDWELL LP | $14732908 | 3458429 | 1.67% | 股份 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $12789240 | 3002169 | 1.45% | 股份 |
| NORTHERN TRUST CORP | $12299856 | 2887290 | 1.39% | 股份 |
| UBS Group AG | $12295344 | 2886231 | 1.39% | 股份 |
| TWO SIGMA INVESTMENTS, LP | $11475213 | 2693712 | 1.30% | 股份 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $11070577 | 2598727 | 1.25% | 股份 |
| BANK OF AMERICA CORP /DE/ | $10074356 | 2364872 | 1.14% | 股份 |
| VANGUARD FIDUCIARY TRUST CO | $9358279 | 2196779 | 1.06% | 股份 |
| GOLDMAN SACHS GROUP INC | $9178165 | 2154499 | 1.04% | 股份 |
| WELLS FARGO & COMPANY/MN | $6289519 | 1476413 | 0.71% | 股份 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $5030221 | 1180803 | 0.57% | 股份 |
| DIMENSIONAL FUND ADVISORS LP | $4661185 | 1094192 | 0.53% | 股份 |
| Caption Management, LLC | $4260000 | 1000000 | 0.48% | 卖出期权 |
| Bank of New York Mellon Corp | $3827454 | 898463 | 0.43% | 股份 |
| CITADEL ADVISORS LLC | $3818068 | 896260 | 0.43% | 股份 |
| J. Goldman & Co LP | $3478669 | 816589 | 0.39% | 股份 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $3019973 | 1232642 | 0.34% | 股份 |
| SCOPIA CAPITAL MANAGEMENT LP | $2960534 | 694961 | 0.34% | 股份 |
| Balyasny Asset Management L.P. | $2914296 | 684107 | 0.33% | 股份 |
| TWO SIGMA ADVISERS, LP | $2897166 | 510964 | 0.33% | 股份 |
| VICTORY CAPITAL MANAGEMENT INC | $2771407 | 650565 | 0.31% | 股份 |
| Nuveen, LLC | $2708218 | 635732 | 0.31% | 股份 |
| Swiss National Bank | $2502324 | 587400 | 0.28% | 股份 |
| STATE OF WISCONSIN INVESTMENT BOARD | $2177052 | 511045 | 0.25% | 股份 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $2106540 | 494493 | 0.24% | 股份 |
| 1492 Capital Management LLC | $2052136 | 481722 | 0.23% | 股份 |
| Mariner, LLC | $2020189 | 474236 | 0.23% | 股份 |
| MILLENNIUM MANAGEMENT LLC | $1836597 | 431126 | 0.21% | 股份 |
| Schonfeld Strategic Advisors LLC | $1774216 | 416483 | 0.20% | 股份 |
| Squarepoint Ops LLC | $1759644 | 413062 | 0.20% | 股份 |
| Jefferies Financial Group Inc. | $1694202 | 397700 | 0.19% | 股份 |
| ExodusPoint Capital Management, LP | $1666261 | 391141 | 0.19% | 股份 |
| JANE STREET GROUP, LLC | $1658418 | 389300 | 0.19% | 买入期权 |
| PRINCIPAL FINANCIAL GROUP INC | $1629561 | 382526 | 0.18% | 股份 |
| Man Group plc | $1624023 | 381226 | 0.18% | 股份 |
| RHUMBLINE ADVISERS | $1604647 | 376681 | 0.18% | 股份 |
激进投资者及 5%+ 股东 2 持仓
提交了 SEC Schedule 13D 的投资者 — 持有超过 5% 的受益所有权，意图影响发行人（激进股东持股、董事会活动、并购）。每一行显示该申报人持仓的最新已知状态。
| 申报人 | 已申报 | 持股 | 状态 | 目的 | 申报 |
|---|---|---|---|---|---|
| Alfred E. Mann, Alfred E. Mann Living Trust, Biomed Partners, LLC, Minimed Infusion, Inc., The Mann Group LLC ×2 申报 | 2012年7月10日 | · | 初始申报 | 被动投资 | SEC |
| 未披露的报告人, 未披露的报告人, 未披露的报告人, 未披露的报告人 | 2006年1月31日 | · | 初始申报 | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
公司内部人士 43 位内幕人士 · 27 位高管 · 19 位董事
| 内部人士 | 角色 | 上次活动 | 持股数量 | 买入 12个月 | 卖出 12个月 | 净额 12个月 |
|---|---|---|---|---|---|---|
| Michael Castagna | Chief Executive Officer | 2026年7月15日 M | 2433779 | 1 | 4 | $-990292 |
| Hakan Edstrom | President & CEO | 2015年8月27日 A | 1114340 | 0 | 0 | $0 |
| Christopher B Prentiss | Chief Financial Officer | 2026年7月15日 F | 318668 | 0 | 0 | $0 |
| Juergen Martens | Corporate VP and COO | 2015年8月27日 A | 106539 | 0 | 0 | $0 |
| Dominic Marasco | Pres, Endocrine Business Unit | 2026年7月15日 F | 343398 | 0 | 0 | $0 |
| Sanjay R Singh | EVP Technical Operations | 2026年7月15日 M | 478966 | 0 | 1 | $-94448 |
| Stuart A Tross | Chief People & Workpl Officer | 2026年7月15日 M | 1058142 | 0 | 1 | $-297548 |
| David Thomson | EVP Genl Counsel & Secretary | 2026年7月15日 M | 797554 | 0 | 3 | $-930755 |
| Ajay Ahuja | Chief Medical Officer | 2026年3月23日 A | 318200 | 0 | 0 | $0 |
| Lauren M Sabella | EVP Operations | 2025年7月15日 F | 349841 | 0 | 0 | $0 |
| Burkhard Blank | EVP Chief Medical Officer | 2025年7月15日 F | 460791 | 0 | 0 | $0 |
| Joseph Kocinsky | Chief Technology Officer | 2022年8月27日 F | 745233 | 0 | 0 | $0 |
| Alejandro Galindo | EVP Endocrine Business Unit | 2022年2月28日 A | 576690 | 0 | 0 | $0 |
| Rosabel Realica Alinaya | VP, IR & Treasury | 2020年8月27日 A | 167119 | 0 | 0 | $0 |
| David M Kendall | Chief Medical Officer | 2020年7月31日 P | 41059 | 0 | 0 | $0 |
| Patrick Mccauley | Chief Commercial Officer | 2020年2月25日 A | 83972 | 0 | 0 | $0 |
| Courtney Barton | Chief Compl & Privacy Officer | 2019年7月31日 P | 29584 | 0 | 0 | $0 |
| Elizabeth Garrett Ingram | Chief Marketing Officer | 2019年5月14日 A | 43012 | 0 | 0 | $0 |
| Raymond W. Urbanski | Corp VP, CMO | 2017年8月10日 S | 2924 | 0 | 0 | $0 |
| Linda A Adreveno | Sr. VP, HR | 2016年2月18日 A | 92200 | 0 | 0 | $0 |
| Alfred E Mann | Executive Chairman | 2015年8月22日 F | 1005990 | 0 | 0 | $0 |
| Diane Palumbo | Vice President, Human Resource | 2015年2月23日 F | 50624 | 0 | 0 | $0 |
| Peter C Richardson | Chief Scientific Officer | 2012年3月3日 F | 133611 | 0 | 0 | $0 |
| Richard L Anderson | Corporate VP | 2008年11月16日 F | 204401 | 0 | 0 | $0 |
| John R. Riesenberger | VP & Chief Commercial Officer | 2008年8月13日 A | 14650 | 0 | 0 | $0 |
| Dan Burns | VP & President, MKBP | 2006年12月8日 A | 14800 | 0 | 0 | $0 |
| Wendell W Cheatham | VP, Medical & Reg Affairs | 2004年8月19日 A | 300 | 0 | 0 | $0 |
| Steven B. Binder | 董事 | 2026年9月25日 S | 713258 | 0 | 5 | $-683703 |
| Sabrina Kay | 董事 | 2026年5月20日 A | 265600 | 0 | 0 | $0 |
| Jennifer Grancio | 董事 | 2026年5月20日 A | 244815 | 0 | 0 | $0 |
| James Samuel Shannon | 董事 | 2026年5月20日 A | 64635 | 0 | 0 | $0 |
| Michael A Friedman | 董事 | 2026年5月20日 A | 47500 | 0 | 0 | $0 |
| Anthony C Hooper | 董事 | 2026年5月20日 A | 236153 | 0 | 0 | $0 |
| Christine Mundkur | 董事 | 2026年5月20日 A | 254493 | 0 | 0 | $0 |
| Ronald J Consiglio | 董事 | 2026年5月20日 A | 132342 | 0 | 0 | $0 |
| Kent Kresa | 董事 | 2024年5月15日 A | 274541 | 0 | 0 | $0 |
| Henry L Nordhoff | 董事 | 2019年5月14日 A | 103426 | 0 | 0 | $0 |
| David Maccallum | 董事 | 2018年5月16日 A | 114790 | 0 | 0 | $0 |
| Matthew J Pfeffer | 董事 | 2017年8月28日 F | 81961 | 0 | 0 | $0 |
| Abraham E Cohen | 董事 | 2012年8月17日 S | 56424 | 0 | 0 | $0 |
| Heather Hay Murren | 董事 | 2008年8月13日 A | 10100 | 0 | 0 | $0 |
| Kathleen Connell | 董事 | 2006年5月25日 A | · | 0 | 0 | $0 |
| Llew Keltner | 董事 | 2006年5月25日 A | · | 0 | 0 | $0 |
来自SEC表格3/4/5申报的内部人士；净额=仅公开市场买卖
ETF持仓 由 29 只交易所交易基金持有
权重仅反映直接股权持仓（N-PORT）；杠杆基金或基于衍生品的基金可能持有未显示的额外掉期敞口。
| 基金 | 权重 | 单位 | 截至 | 来源 |
|---|---|---|---|---|
| JSMD · Janus Detroit Street Trust | 0.62% | 1678187 NS | 2026年7月31日 | N-PORT |
| QQQS · Invesco Exchange-Traded Fund Trus... | 0.50% | 29891 SH | 2026年10月1日 | 每日 |
| JSML · Janus Detroit Street Trust | 0.49% | 450643 NS | 2026年7月31日 | N-PORT |
| FYC · First Trust Exchange-Traded Alpha... | 0.37% | 1212660 NS | 2026年7月31日 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0.23% | 289432 NS | 2026年7月31日 | N-PORT |
| FYX · First Trust Exchange-Traded Alpha... | 0.12% | 409547 NS | 2026年7月31日 | N-PORT |
| IBB · iShares Trust | 0.08% | 2264902 SH | 2026年9月11日 | 每日 |
| IBBQ · Invesco Exchange-Traded Fund Trus... | 0.08% | 22737 SH | 2026年10月1日 | 每日 |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0.08% | 330117 SH | 2026年8月19日 | 每日 |
| IWO · iShares Trust | 0.08% | 2877921 SH | 2026年9月11日 | 每日 |
| FAD · First Trust Exchange-Traded Alpha... | 0.07% | 109855 NS | 2026年7月31日 | N-PORT |
| PWS · Pacer Funds Trust | 0.06% | 3954 NS | 2026年7月31日 | N-PORT |
| ESML · iShares Trust | 0.05% | 333357 SH | 2026年9月11日 | 每日 |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.04% | 1771496 SH | 2026年8月19日 | 每日 |
| RSSL · Global X Funds | 0.04% | 147059 NS | 2026年7月31日 | N-PORT |
| ISCG · iShares Trust | 0.04% | 96772 SH | 2026年9月11日 | 每日 |
| IWM · iShares Trust | 0.04% | 7845946 SH | 2026年9月11日 | 每日 |
| VHT · VANGUARD WORLD FUND | 0.02% | 874372 SH | 2026年8月19日 | 每日 |
| FHLC · FIDELITY COVINGTON TRUST | 0.02% | 139696 NS | 2026年7月31日 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0.01% | 3543398 SH | 2026年8月19日 | 每日 |
| WSML · iShares Trust | 0.01% | 16637 SH | 2026年9月11日 | 每日 |
| TILT · FlexShares Trust | 0.00% | 23700 NS | 2026年7月31日 | N-PORT |
| ITOT · iShares Trust | 0.00% | 465405 SH | 2026年9月11日 | 每日 |
| IWV · iShares Trust | 0.00% | 84120 SH | 2026年9月10日 | 每日 |
| DFAC · Dimensional ETF Trust | 0.00% | 58407 NS | 2026年7月31日 | N-PORT |
| DFAS · Dimensional ETF Trust | 0.00% | 11291 NS | 2026年7月31日 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 9327332 SH | 2026年8月19日 | 每日 |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.00% | 26184 SH | 2026年8月19日 | 每日 |
| ISCB · iShares Trust | · | 13557 SH | 2026年9月11日 | 每日 |
MNKD 分析师共识 看涨和看跌分析师观点、12个月价格目标、上涨空间
评级 · 14 位分析师
买入
中位数目标
$7.50
+97.4%
4 28.6%
强烈买入
8 57.1%
买入
2 14.3%
持有
0 0.0%
卖出
0 0.0%
强烈卖出
12个月价格目标
8 位分析师 · 2026-09-28平均目标 $7.97 +109.7%
← 低于所有目标
当前价格 $3.80
最低$4.75
平均值$7.97
最高$13.00
同行比较（GICS 子行业） 关键指标与行业同行对比
财年依据，价格截至各公司上一个财年末收盘价。
| 股票代码 | 市值 | P/E | 营收同比增长 | 净利润率 | ROE | 毛利率 |
|---|---|---|---|---|---|---|
| MNKD | $1.75B | 283.5 | 22.2% | 1.7% | -11.1% | · |
| ORIC | $806M | -5.6 | · | · | -36.5% | · |
| DMRA | · | · | 38.3% | -17981.1% | -167.0% | · |
| REPL | $633M | -2.3 | · | · | -146.2% | · |
| TRAX | · | · | · | · | · | · |
| BCAX | $953M | -6.7 | · | · | -33.0% | · |
| VOR | $506M | -0.2 | · | · | 83.4% | · |
| MGTX | $645M | -5.6 | 144.6% | -140.3% | 8062.2% | · |
| JANX | $833M | -7.5 | -5.5% | -1136.2% | -11.7% | · |
最新新闻 提及该公司的近期头条新闻
Wells Fargo Calls MannKind Corporation (MNKD)’s Commercial Potential a “Show-Me Story”
Yahoo Finance · 3 月，2 周 前
MannKind (MNKD) Advances Clinical Trials for Inhaled IPF Therapy
Yahoo Finance · 3 月，3 周 前
H.C. Wainwright and Wells Fargo Lift MannKind (MNKD) Price Targets
Yahoo Finance · 4 月，2 周 前
曼奈基因公司（MNKD）是否是罗宾汉购买的热门便士股票之一？
Yahoo Finance · 6 月 前
交易信号 近期买入/卖出信号，包含入场价和风险/回报比
目前没有公开信号 — 没有卡片被填写，这是诚实的。
我的指标 您的个人关注列表 — 来自完整基本面的选定行
选择对您重要的指标 — 点击上方完整基本面中任意行的 + 号。
您的选择已保存，并会跟随您浏览所有股票。
来源：SEC 10-Q 于 八月 5, 2026 申报